InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,422.82
(
1.47%
)
US TECH 100
18,471.20
(
2.30%
)
Dow Jones
39,695.29
(
0.86%
)
Brent Oil
80.31
(
-1.59%
)
Bitcoin
60,989.58
(
2.75%
)
Post# of 252870
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120264
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 116132

Tuesday, 03/08/2011 5:26:53 PM

Tuesday, March 08, 2011 5:26:53 PM

Post# of 252870
Unlike Teva (who has sought to hide the origins of its Lovenox knockoff), MYL has been candid in acknowledging that its version of Copaxone is the same drug Natco sells as a Copaxone knockoff in India.

I don’t think MYL has a serious chance of getting FDA approval, whether or not they opt to run a clinical trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up